Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer

42Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

Objective. To compare 14-gauge SCNB (stereotactic core needle biopsy) with surgery and to investigate tissue-heterogeneity of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth-factor receptor (HER-2) for non-palpable breast cancers. To determine the number of cores needed for assessment of these factors. Materials and methods. Cores of 41 invasive cancers were collected in three containers: the 1st into A, the 2nd and 3rd into B and subsequent cores into C. ER, PR and HER-2 were scored by immunohistochemistry and if 2+ or 3+, by chromogenic-in-situ-hybridisation (CISH) for containers and for surgical specimen. Results. Between SCNB and surgical specimen concordance was 83% (κ=0.39) for ER, 88% (κ=0.69) for PR and HER-2 and 93% (κ=0.63) for HER-2 after CISH. For the most discordant cases, status was positive in cores but negative in surgery: 5/7 for ER (p=0.459), 5/5 for PR (p=0.063), and 4/5 for HER-2 (p=0.375), after CISH 3/3 (p=0.250), but the difference was not statistically significant. Concordances between containers of cores was 100% (κ=1), 85% (κ=0.66) and 85% (κ=0.66), respectively. With more than three cores, sensitivities of 95%, 100% and 100% were reached. Conclusions. SCNB is at least as sensitive as surgery in assessment of ER, PR and HER-2. Three cores are needed for reliable assessment of HER-2 after adding CISH and more than three cores for PR, possibly due to tissue heterogeneity. For ER sensitivity remained lower, 95%, even in multiple cores, therefore ER-negative cases should be further investigated from surgical specimens. © 2008 Taylor & Francis.

Cite

CITATION STYLE

APA

Sutela, A., Vanninen, R., Sudah, M., Berg, M., Kiviniemi, V., Rummukainen, J., … Kärjä, V. (2008). Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer. Acta Oncologica, 47(1), 38–46. https://doi.org/10.1080/02841860701441822

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free